Form 8-K - Current report:
SEC Accession No. 0001140361-22-044329
Filing Date
2022-12-05
Accepted
2022-12-05 06:02:11
Documents
14
Period of Report
2022-12-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10045002_8k.htm   iXBRL 8-K 31706
2 EXHIBIT 10.1 brhc10045002_ex10-1.htm EX-10.1 109619
3 EXHIBIT 10.2 brhc10045002_ex10-2.htm EX-10.2 194585
  Complete submission text file 0001140361-22-044329.txt   526151

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA erna-20221202.xsd EX-101.SCH 3866
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20221202_lab.xml EX-101.LAB 22547
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20221202_pre.xml EX-101.PRE 16045
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10045002_8k_htm.xml XML 4238
Mailing Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121
Business Address 10355 SCIENCE CENTER DRIVE SUITE 150 SAN DIEGO CA 92121 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221443665
SIC: 2834 Pharmaceutical Preparations